Try

AVANOS MEDICAL, INC.

AVNSUnited States

44 filed reports · 508 financial concepts

Latest figures

Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.

FigureLatest fiscal yearLatest quarter
Revenue$701MFY2025 · to Dec 31, 2025+1.9% from $688M10-K$182MQ1 FY2026 · to Mar 31, 2026+8.8% from $168M10-Q
Net income-$72.9MFY2025 · to Dec 31, 2025a year earlier: -$392M10-K$5.1MQ1 FY2026 · to Mar 31, 2026−22.7% from $6.6M10-Q
Operating income-$61.6MFY2025 · to Dec 31, 2025a year earlier: -$396M10-K$8.9MQ1 FY2026 · to Mar 31, 2026−13.6% from $10.3M10-Q

Filed reports

44 reports · Jun 2015 to Mar 2026

Each report counts once it has at least one extracted financial fact.

Report typeReportsFactsPeriods
Quarterly · 10-QSEC EDGAR325,379Jun 2015 to Mar 2026
Annual · 10-KSEC EDGAR115,537Dec 2015 to Dec 2025
Quarterly · 10-Q/ASEC EDGAR1190Sep 2018

Documents

PeriodTypePeriod endPublishedFactsSource
FY2026 Q110-QMar 31, 2026May 5, 2026360Open
FY202510-KDec 31, 2025Feb 24, 2026946Open
FY2025 Q310-QSep 30, 2025Nov 5, 2025256Open
FY2025 Q210-QJun 30, 2025Aug 5, 2025249Open
FY2025 Q110-QMar 31, 2025May 6, 2025178Open
FY202410-KDec 31, 2024Feb 26, 2025487Open
FY2024 Q310-QSep 30, 2024Oct 30, 2024156Open
FY2024 Q210-QJun 30, 2024Jul 31, 2024150Open
FY2024 Q110-QMar 31, 2024May 2, 2024147Open
FY202310-KDec 31, 2023Feb 21, 2024445Open
FY2023 Q310-QSep 30, 2023Nov 1, 2023161Open
FY2023 Q210-QJun 30, 2023Aug 9, 2023146Open

Financial data

508 concepts · 11,106 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial482 concepts · 10,414 facts · Dec 2013 to Mar 2026

  • Cash and cash equivalents at carrying value62 · Dec 2013 to Mar 2026
  • Comprehensive income net of tax62 · Dec 2013 to Mar 2026
  • Depreciation62 · Dec 2013 to Mar 2026
  • Gross profit (US GAAP)62 · Dec 2013 to Mar 2026
  • Income tax expense benefit62 · Dec 2013 to Mar 2026
  • Investment income interest62 · Dec 2013 to Mar 2026
  • Net income loss62 · Dec 2013 to Mar 2026
  • Operating income loss62 · Dec 2013 to Mar 2026
  • Other comprehensive income foreign currency transaction and translation adjustment net of tax portion attributable to parent62 · Dec 2013 to Mar 2026
  • Other comprehensive income loss net of tax portion attributable to parent62 · Dec 2013 to Mar 2026
  • Other operating income expense net62 · Dec 2013 to Mar 2026
  • Research and development expense62 · Dec 2013 to Mar 2026
  • Selling general and administrative expense62 · Dec 2013 to Mar 2026
  • Accrued Compensation Benefits61 · Dec 2014 to Mar 2026
  • Amortization of intangible assets61 · Dec 2013 to Dec 2025
  • Depreciation depletion and amortization60 · Dec 2013 to Mar 2026
  • Income loss from continuing operations before income taxes extraordinary items noncontrolling interest60 · Dec 2013 to Mar 2026
  • Increase decrease in accounts payable trade60 · Dec 2013 to Mar 2026
  • Increase decrease in accounts receivable60 · Dec 2013 to Mar 2026
  • Increase decrease in accrued liabilities60 · Dec 2013 to Mar 2026
  • Increase decrease in inventories60 · Dec 2013 to Mar 2026
  • Increase decrease in prepaid deferred expense and other assets60 · Dec 2013 to Mar 2026
  • Net cash provided by used in financing activities60 · Dec 2013 to Mar 2026
  • Net cash provided by used in investing activities60 · Dec 2013 to Mar 2026

Segment23 concepts · 431 facts · Dec 2013 to Mar 2026

  • Revenue86 · Dec 2013 to Mar 2026
  • Operating income loss47 · Dec 2013 to Sep 2018
  • Cost of goods and services sold (US GAAP)27 · Dec 2022 to Mar 2026
  • General and administrative expense (US GAAP)27 · Dec 2022 to Mar 2026
  • Net income loss27 · Dec 2022 to Mar 2026
  • Production and distribution costs27 · Dec 2022 to Mar 2026
  • Research and development expense27 · Dec 2022 to Mar 2026
  • Advertising, Promotion And Selling Expenses23 · Dec 2022 to Mar 2026
  • Depreciation And Amortization Expense23 · Dec 2022 to Mar 2026
  • Goodwill foreign currency translation gain loss22 · Dec 2015 to Mar 2026
  • Other Operating Income (Expense), Excluding DepreciationAnd Amortization, Net19 · Dec 2022 to Mar 2026
  • Goodwill impairment loss14 · Sep 2015 to Dec 2025
  • Goodwill translation adjustments14 · Dec 2014 to Sep 2016
  • Goodwill acquired during period10 · Sep 2016 to Dec 2025
  • Depreciation depletion and amortization9 · Dec 2013 to Dec 2017
  • Payments to acquire productive assets9 · Dec 2013 to Dec 2017
  • Goodwill and intangible asset impairment3 · Dec 2022 to Dec 2024
  • Income loss from continuing operations3 · Dec 2022 to Dec 2024
  • Income loss from discontinued operations net of tax attributable to reporting entity3 · Dec 2022 to Dec 2024
  • Income tax expense benefit3 · Dec 2022 to Dec 2024
  • Interest expense nonoperating3 · Dec 2022 to Dec 2024
  • Investment income interest3 · Dec 2022 to Dec 2024
  • Goodwill, Change In Goodwill Allocation, Segments2 · Dec 2025

Product2 concepts · 247 facts · Dec 2016 to Mar 2026

  • Revenue244 · Dec 2016 to Mar 2026
  • Inventory write down3 · Dec 2020 to Dec 2022

Geography1 concept · 14 facts · Dec 2013 to Dec 2025

  • Revenue14 · Dec 2013 to Dec 2025

Segments

692 facts

Figures broken down by business line, region, product or another axis the company reports on.

Statement business segments6 members · 431 facts

  • Total Pain Management and Recovery112 · Dec 2023 to Mar 2026
  • Total Specialty Nutrition Systems112 · Dec 2023 to Mar 2026
  • Medical Devices84 · Dec 2013 to Sep 2018
  • S&IP66 · Dec 2013 to Sep 2017
  • Reportable segment45 · Dec 2022 to Dec 2024
  • Corporate and other12 · Dec 2023 to Mar 2026

Product or servicesrt:ProductOrServiceAxis14 members · 243 facts

  • Chronic care33 · Dec 2016 to Mar 2023
  • Pain management33 · Dec 2016 to Mar 2023
  • Digestive health22 · Dec 2019 to Dec 2024
  • Interventional pain22 · Dec 2019 to Dec 2024
  • Surgical pain and recovery22 · Dec 2021 to Mar 2026
  • Total Pain Management and Recovery22 · Dec 2021 to Mar 2026
  • Acute pain13 · Dec 2019 to Mar 2023
  • Respiratory health13 · Dec 2019 to Mar 2023
  • Corporate and Other12 · Dec 2023 to Mar 2026
  • Enteral feeding12 · Dec 2023 to Mar 2026
  • Neonate solutions12 · Dec 2023 to Mar 2026
  • Radiofrequency ablation12 · Dec 2023 to Mar 2026
  • Total Specialty Nutrition Systems12 · Dec 2023 to Mar 2026
  • Halyard-branded Products3 · Dec 2020 to Dec 2022

Statement geographicalsrt:StatementGeographicalAxis1 member · 10 facts

  • United States10 · Dec 2016 to Dec 2025

Product or serviceus-gaap:ProductOrServiceAxis2 members · 4 facts

  • Chronic care2 · Mar 2017 to Mar 2018
  • Pain management2 · Mar 2017 to Mar 2018

Statement geographicalus-gaap:StatementGeographicalAxis1 member · 4 facts

  • United States4 · Dec 2013 to Dec 2016

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

Earnings calls

Transcripts with management claims and analyst questions, one per fiscal period.

No earnings-call transcripts for this company.

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Ask about this company in your AI model

Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.

Use FactIQ to get the revenue, net income and operating income of AVANOS MEDICAL, INC. (AVNS) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 16, 2026) and refreshed every few hours.